Jara A, Lee E, Stauber D, Moatamed F, Felsenfeld A J, Kleeman C R
Division of Nephrology, West Los Angeles VA Medical Center, USA.
Kidney Int. 1999 Apr;55(4):1434-43. doi: 10.1046/j.1523-1755.1999.00395.x.
The removal of phosphate from the diet of the growing rat rapidly produces hypercalcemia, hypophosphatemia, hypercalciuria, and hypophosphaturia. Increased calcium efflux from bone has been shown to be the important cause of the hypercalcemia and hypercalciuria. It has been proposed that the increased calcium efflux from bone is osteoclast mediated. Because bisphosphonates have been shown to inhibit osteoclast-mediated bone resorption, this study was performed to determine whether bisphosphonate-induced inhibition of osteoclast function changed the biochemical and bone effects induced by phosphate depletion.
Four groups of pair-fed rats were studied: (a) low-phosphate diet (LPD; phosphate less than 0.05%), (b) LPD plus the administration of the bisphosphonate Pamidronate (APD; LPD + APD), (c) normal diet (ND, 0.6% phosphate), and (d) ND + APD. All diets contained 0.6% calcium. A high dose of APD was administered subcutaneously (0.8 mg/kg) two days before the start of the study diet and on days 2, 6, and 9 during the 11 days of the study diet. On day 10, a 24-hour urine was collected, and on day 11, rats were either sacrificed or received an additional APD dose before a 48-hour parathyroid hormone (PTH) infusion (0.066 microgram/100 g/hr) via a subcutaneously implanted miniosmotic pump.
Serum and urinary calcium were greater in the LPD and LPD + APD groups than in the ND and ND + APD groups [serum, 11.12 +/- 0.34 and 11.57 +/- 0.45 vs. 9.49 +/- 0.17 and 9.48 +/- 0.15 mg/dl (mean +/- SE), P < 0.05; and urine, 8.78 +/- 2.74 and 16.30 +/- 4.68 vs. 0.32 +/- 0.09 and 0.67 +/- 0.28 mg/24 hr, P < 0.05]. Serum PTH and serum and urinary phosphorus were less in the LPD and LPD + APD than in the ND and ND + APD groups (P < 0.05). The calcemic response to PTH was less (P < 0.05) in the LPD and LPD + APD groups than in the ND group and was less (P = 0.05) in the LPD + APD than in the ND + APD group. Bone histology showed that phosphate depletion increased the osteoblast and osteoclast surface, and treatment with APD reduced the osteoblast surface (LPD vs. LPD + APD, 38 +/- 4 vs. 4 +/- 2%, P < 0.05, and ND vs. ND + APD, 20 +/- 2 vs. 5 +/- 2%, P < 0.05) and markedly altered osteoclast morphology by inducing cytoplasmic vacuoles.
(a) Phosphate depletion induced hypercalcemia and hypercalciuria that were not reduced by APD administration. (b) The calcemic response to PTH was reduced in phosphate-depleted rats and was unaffected by APD administration in normal and phosphate-depleted rats, and (c) APD administration markedly changed bone histology without affecting the biochemical changes induced by phosphate depletion.
快速去除生长中大鼠饮食中的磷酸盐会迅速导致高钙血症、低磷血症、高钙尿症和低磷尿症。已表明骨中钙流出增加是高钙血症和高钙尿症的重要原因。有人提出骨中钙流出增加是由破骨细胞介导的。由于双膦酸盐已被证明可抑制破骨细胞介导的骨吸收,因此进行本研究以确定双膦酸盐诱导的破骨细胞功能抑制是否会改变磷酸盐缺乏诱导的生化和骨骼效应。
研究了四组配对喂养的大鼠:(a) 低磷饮食(LPD;磷酸盐含量低于0.05%),(b) LPD加双膦酸盐帕米膦酸盐给药(APD;LPD + APD),(c) 正常饮食(ND,0.6% 磷酸盐),以及(d) ND + APD。所有饮食均含0.6% 钙。在研究饮食开始前两天以及研究饮食的11天中的第2、6和9天,皮下注射高剂量的APD(0.8 mg/kg)。在第10天,收集24小时尿液,在第11天,处死大鼠或在通过皮下植入的微型渗透泵进行48小时甲状旁腺激素(PTH)输注(0.066微克/100克/小时)之前再给予一次APD剂量。
LPD和LPD + APD组的血清和尿钙高于ND和ND + APD组[血清,11.12±0.34和11.57±0.45 vs. 9.49±0.17和9.48±0.15毫克/分升(平均值±标准误),P < 0.05;尿钙,8.78±2.74和16.30±4.68 vs. 0.32±0.09和0.67±0.28毫克/24小时,P < 0.05]。LPD和LPD + APD组的血清PTH以及血清和尿磷低于ND和ND + APD组(P < 0.05)。LPD和LPD + APD组对PTH的血钙反应低于ND组(P < 0.05),且LPD + APD组低于ND + APD组(P = 0.05)。骨组织学显示,磷酸盐缺乏增加了成骨细胞和破骨细胞表面,而APD治疗减少了成骨细胞表面(LPD组与LPD + APD组,38±4 vs. 4±2%,P < 0.05;ND组与ND + APD组,20±2 vs. 5±2%,P < 0.05),并通过诱导细胞质空泡显著改变了破骨细胞形态。
(a) 磷酸盐缺乏诱导的高钙血症和高钙尿症不会因APD给药而减轻。(b) 磷酸盐缺乏的大鼠对PTH的血钙反应降低,正常和磷酸盐缺乏的大鼠中APD给药对此无影响,且(c) APD给药显著改变了骨组织学,但不影响磷酸盐缺乏诱导的生化变化。